Semaglutide 7.2 mg led to up to 21% weight loss, with one-third of participants losing ≥25% body weight in the STEP UP trial.
The STEP UP findings further strengthen the evidence supporting WEGOVY’s ability to deliver substantial weight loss and meaningful health benefits for individuals with obesity.
WEGOVY (semaglutide 2.4 mg) is already approved in the EU and the US as part of a comprehensive weight management approach. At the 2025 ADA Scientific Sessions in Chicago, Novo Nordisk presented new data from the Phase IIIb STEP UP program, spotlighting the potential of a higher 7.2 mg dose of semaglutide in individuals with obesity, both with and without T2D.
...
